
GLP-1 Drugs May Signal Higher Cognitive-Impairment Risk, Possibly Due to Longer Lifespans
A Johns Hopkins-led retrospective analysis of TriNetX data from ~65,000 older adults with type 2 diabetes found higher rates of cognitive impairment among GLP-1 agonist users (2.6%) versus non-users (1.3%). The authors caution the finding may reflect a survival effect—GLP-1 users live longer and thus have more time to develop cognitive issues—and that causality cannot be inferred from retrospective data; more research is needed to clarify any true risk.













